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Computer-based (in silico) modeling & simulation tools have been embraced in different 
fields of pharmaceutics for a variety of applications. Among these, physiologically-based 
pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) emerged as a particularly useful 
tool in formulation development. PBPK/PBBM facilitated strategies have been increasingly 
evaluated over the past few years, as demonstrated by several reports from the pharmaceutical 
industry, and a number of research and review papers on this subject. Also, the leading regulatory 
authorities have recently issued guidance on the use of PBPK modeling in formulation design. In 
silico PBPK models can comprise different dosing routes (oral, intraoral, parenteral, inhalation, 
ocular, dermal etc.), although the majority of published examples refer to modeling of oral drugs 
performance. In order to facilitate the use of PBPK modeling tools, a couple of companies have 
launched commercially available software such as GastroPlus™, Simcyp™ PBPK Simulator and 
PK-Sim®. This paper highlights various application fields of PBPK/PBBM modeling, along with 
the basic principles, advantages and limitations of this approach, and provides relevant examples 
to demonstrate the practical utility of modeling & simulation tools in different stages of 
formulation development. 
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Cost- and time-effective formulation design is an imperative for the highly 
competitive pharmaceutical industry. In order to handle such challenges, pharmaceutical 
companies have to move from traditional trial & error based strategies in formulation 
development, and adopt novel, more sophisticated methods, such as Quality by Design 
tools (e.g., design of experiments, machine learning tools) and/or in silico modeling & 
simulation (M & S) tools. This last approach is known as model informed drug 
development (MIDD) and it encompasses a range of quantitative models in formulation 
development used to facilitate decision making processes (1). MIDD methods are known 
under different names, depending on the principle and objective of the modeling process. 
The most commonly used approach refers to the so called physiologically-based 
pharmacokinetic modeling (PBPK) as a tool to mechanistically interpret and predict 
absorption, distribution, metabolism and excretion (ADME) properties of drugs in the 
human body (2). PBPK models can be extended to simulate drugs pharmacodynamic 
(PD) effects, which are then recognized as PBPK/PD models. More recently, a novel term 
physiologically-based biopharmaceutics modeling (PBBM) has been introduced to 
describe the modeling approach primarily orientated toward establishing a link between 
biopredictive in vitro dissolution testing and mechanistic drug absorption modeling (3). 
In all of these models, the data derived from preclinical and clinical studies are used to 
predict the expected biological effects/parameters of interest and clarify the underlying 
physiological processes. 
Structure and performance of PBPK/PBBM models 
Physiologically-based modeling of a drug’s ADME properties is based on three sets 
of input data comprising drug biopharmaceutical (physicochemical and pharmacokinetic) 
properties, formulation properties and physiological characteristics of the target 
population/population representative. The necessary input data can be derived from 
various sources, including experimental (in house data or literature values) and in silico 
predicted values. The interplay between these parameters and the resulting influence on 
drug bioperformance is modeled by a series of linked differential equations (4). 
The correct representation of the physiology of interest and the underlying 
physiological processes governing drug bioperformance is a major challenge in the design 
of PBPK/PBBM models (5). Physiological data are usually extracted from literature and 
refer to the mean data for the population of interest. However, these data are sometimes 
difficult to obtain due to the limited information or lack of knowledge, particularly 
concerning special populations such as paediatrics, geriatrics, pregnant women and 
various disease populations (6). There has been a number of examples illustrating the use 
of in house designed PBPK models, including both relatively simple and more complex 
models (7-11). However, nowadays it is more common to use commercially available 
software packages such as GastroPlus™ (https://www.simulations-
plus.com/software/gastroplus/), Simcyp™ PBPK Simulator 




biology.com/products/PK-Sim/). These software packages represent a user-friendly 
alternative to the in house models, since they integrate relevant physiological data on 
different populations, along with the required mathematical background, and are ready to 
use in terms of computer programming.  
The available software can be used to simulate drug absorption and/or disposition 
from different dosage forms, following various administration routes (oral (peroral), 
intraoral, intravenous, intramuscular, subcutaneous, inhalation, ocular, dermal, intra-
articular), at different stages (fasted, fed) and in different population groups regarding age 
(adults, paediatrics, geriatrics), health and other statuses (healthy, pregnancy state, certain 
disease states), ethnicity (e.g. Caucasian (Western), Japanese, Chinese populations) 
and/or enzyme expression levels. Moreover, the simulations can be performed for a 
population representative, but also for a group of subjects when the model accounts for 
interindividual variability in the physiological parameters and other input values. 
Software from different suppliers have certain specificities, but in general they all 
comprise representation of major organs/tissues connected with systemic circulation. 
Figure 1 illustrates an example model integrated in the GastroPlus™ software package. 
The Advanced Compartmental Absorption and Transit (ACAT) model provides a detailed 
representation of the human gastrointestinal (GI) tract and the processes a drug undergoes 
in different GI regions. The underlying theory and basic principles of the ACAT model 
have been described in the review papers of Agoram et al. (12) and Lin and Wong (13). 
The ACAT model is connected with the compartmental pharmacokinetic model (up to 
three compartments) or full/whole body PBPK model to simulate drug disposition and 
metabolism. The compartmental model is relatively simple but requires a priory 
knowledge of drug’s pharmacokinetic data (i.e., clearance, volume of distribution, 
distribution constants). On the other hand, full PBPK model represents a system of 
organs/tissues, described by relevant physiological parameters, whereat a drug 
disposition within each organ/tissue is described as either perfusion-limited or 

















Figure 1.  Schematic representation of the models incorporated in GastroPlus™  
 software  
Slika 1.  Shematski prikaz modela inkorporiranih u GastroPlus™ softver 
 
The software packages are continuously being upgraded, and some of the 
improvements include the addition of detailed models to describe drug performance 
following alternative dosing routes. Currently available models (modules) in 




these models are still in a pioneer phase, and there are not many literature reports on their 
use, although the OCCAT™ and PCAT™ models have been explored somewhat more 
(16-28). The OCCAT™ model is designed to simulate drug absorption from the oral 
cavity, and consists of six compartments connected by blood and saliva flows. The model 
is linked to the ACAT™ model, in order to predict the absorption of the swallowed dose 
fraction (16). The PCAT™ model simulates the processes a drug undergoes in the 
respiratory tract following intranasal, intratracheal or pulmonary administration. It 
consists of distinct, but interconnected pulmonary compartments, linked with the rest of 
the body via systemic circulation to simulate the disposition of drug absorbed through the 
lungs, and the ACAT™ model to predict absorption of the swallowed part of the dose 
(28). PCAT™ also comprises built-in models to estimate regional drug deposition.  
 
 
Figure 2.  Additional models (modules) in the GastroPlus™ software (Transdermal  
 Compartmental Absorption and Transit (TCAT™) model; Pulmonary  
 Compartmental Absorption and Transit (PCAT™) model; Ocular  
 Compartmental Absorption and Transit (OCAT™) model; Oral Cavity  
 Compartmental Absorption and Transit (OCCAT™) model; immediate- 
 release (IR); controlled-release (CR)) 
Slika 2.  Dodatni modeli (moduli) u okviru GastroPlus™ softvera (Transdermalni  
 prostorni model za simulaciju apsorpcije i transporta lekovite supstance  
 (TCAT™); Prostorni model pluća za simulaciju apsorpcije i transporta  
 lekovite supstance (PCAT™); Prostorni model oka za simulaciju apsorpcije  
 i transporta lekovite supstance (OCAT™); Prostorni model usne duplje za  
 simulaciju apsorpcije i transporta lekovite supstance (OCCAT™); trenutno  





The application field of PBPK/PBBM models is wide, but prior to application a 
model needs to be set and, if possible, validated. In most cases, this is the lengthiest step 
of the M & S process. Each model is drug-specific and the necessary input data have to 
be collected (preferably experimentally) and carefully analyzed. Also, if some of the 
parameters are missing, they need to be optimized. The validation phase applies for cases 
with available reference data from clinical studies. In such cases, clinical data can also be 
used as inputs in the model (top-down approach) or to refine the model and validate the 
prediction results (middle-out approach). However, in early phases of drug development, 
the simulations can be performed solely based on the preclinical and/or in silico predicted 
data (bottom-up approach), implying that the prediction results might be associated with 
a level of uncertainty.  
The core interest in PBPK/PBBM lies in the ability of these models to predict the 
expected drug absorption and bioavailability in the formulation development phase, prior 
to clinical studies, or in line with the post approval changes, to assess the impact of 
variations in drug product on its bioperformance. Common objectives of PBPK/PBBM 
modeling are denoted on Figure 3, and the selected examples referring to the use of these 
models in formulation development are described in the following section.   
 
 
Figure 3.  Application of PBPK/PBBM modeling 





Application of PBPK/PBBM modeling in formulation development 
A plethora of published papers demonstrate the emerging role of M & S tools in 
pharmaceutical development, mostly for oral dosage forms, but there are also some 
examples referring to dosage forms for alternative dosing routes.  
One of the key features of PBPK/PBBM models is sensitivity analysis (SA) used to 
assess the sensitivity of output values (e.g., drug’s absorption and bioavailability) to the 
changes in the input variables (e.g., drug and formulation properties such as particle size, 
solubility, dissolution rate or physiology characteristics such as GI pH, transit time etc.). 
In this way, SA allows the identification of critical factors affecting the rate and extent of 
drug absorption prior to formulation development or assessment of the impact of 
formulation variations in the post-approval phase. SA can also be used to understand the 
possible reasons for poor drug bioavailability or inter-subject/inter-population variability. 
To exemplify, a case study for a poorly soluble candidate drug illustrates the utility of in 
silico modeling to guide the formulation design of a drug product that would diminish the 
effect of medium pH on drug dissolution and absorption. In this case, the model drug was 
a weak base with pH-dependent solubility in the GI pH range, implying that patients with 
achlorhydria or patients taking antacids, H2-blockers or proton pump inhibitors may 
suffer from reduced drug absorption due to potential precipitation under the elevated 
gastric pH. Therefore, a drug-specific model was constructed in GastroPlus™, and SA 
for the two selected variables (gastric pH and drug particle size) revealed that, if particle 
size is held below a certain limit (100 μm), medium pH is not expected to significantly 
influence drug dissolution and absorption. This case demonstrated that a relatively simple 
formulation strategy may overcome problems with reduced drug bioavailability in certain 
patient groups. Moreover, these in silico data were used to justify drug particle size limits 
within the quality specification included in the regulatory submission (29). Similar 
examples on using in silico modeling and SA to establish drug particle size specifications 
were described in the papers of Wei and associates (30), and Kesisoglou & Wu (31). 
Reports on using SA as part of the formulation development strategy are numerous, but 
they generally consider the assessment of particular model variables. There is also an 
example of a more general approach applied by Melillo et al. (32) who described the use 
of in house (MATLAB) created PBPK models in combination with global sensitivity 
analysis to identify the key parameters affecting the absorption and bioavailability of 
drugs in relation to their biopharmaceutical properties (i.e., Biopharmaceutics 
Classification System (BCS) class). According to the modeling results, formulation 
properties might influence bioperformance of all BCS drug classes, while the absorption-
related parameters are mainly expected to influence fraction absorbed of poorly 
permeable drugs. 
In extension to SA, PBPK programs also allow population simulations in a group 
of virtual subjects to anticipate the inter-population or inter-subject variability on drug 
ADME properties. This approach is particularly useful in the design of dosage forms for 
special populations e.g., age-appropriate formulations for paediatric patients. For 




adolescents to evaluate the exposure of extended-release (ER) formulation in relation to 
immediate-release (IR) one. More recently, Vaidhyanathan et al. (34) reported the use of 
PBPK modeling to evaluate the rate and extent of dasatinib absorption from IR tablet and 
a pediatric powder for oral suspension. There is also a published example of more specific 
PBPK modeling for paediatric patients who underwent renal transplantation. The authors 
tested the scenario when a patient switches from fast-release to sustained-release 
tacrolimus formulations, and based on the modeling outputs, they were able to provide 
personalized recommendations on drug dosing (35). PBPK modeling orientated toward 
providing proper dosing recommendations was also reported for geriatric patients (36-
38) and certain disease populations (39-41).  
Contemporary trends in pharmaceutical development emphasize the benefits of 
novel drug delivery systems and advanced formulation technologies, and PBPK/PBBM 
modeling has also been applied to elucidate the outcomes of such formulation approaches. 
An interesting example refers to the application of PBBM approach to identify 
simvastatin formulations with increased oral bioavailability. Simvastatin is a poorly 
soluble lactone prodrug susceptible to extensive pre-systemic metabolism in the gut wall 
and liver, and in silico modeling revealed that mere improvement in drug solubility (e.g., 
by formulating drug-loaded self-microemulsifying drug delivery system (SMEDDS)) 
will have no effect on drug plasma exposure. But, the formulation of oral dosage forms 
that release the drug in a pre-solubilized form in distal parts of the intestine (e.g., 
SMEDDS filled in acid-resistant capsules or lipid-based drug delivery systems with 
polymethacrylate polymers as solid carriers) might improve simvastatin bioavailability 
by more than 50% in comparison to conventional IR dosage form (42, 43). Another 
example described the use of in vitro-in silico modeling to assess the potential of solid 
dispersions to improve the dissolution rate and bioavailability of valsartan. This study 
suggested that solid dispersion-based oral formulations may largely increase valsartan 
bioavailability in comparison to conventional IR capsules (44). In vitro-in silico modeling 
approach was also used to elucidate the combined effect of drug/formulation and 
physiological factors on ranitidine absorption and optimize the design of gastroretentive 
floating system for sustained release of ranitidine (45). A review of Yuan et al. (46) 
summarizes the efforts to characterize the absorption and disposition of nanoparticles for 
different administration routes using PBPK modeling. This approach is still associated 
with many challenges but is expected to progress in the future years. 
Another way to explore M & S is to assess the relationship between the in vitro and 
in vivo data (in vitro-in vivo correlation/relationship, IVIVC/IVIVR) so that in vitro 
dissolution test can be used to identify drug/formulation factors which may affect the 
bioperformance of a drug product (47-49). Such an approach can also be used to justify 
biowaivers i.e., the substitution of the in vivo bioequivalence studies with the relevant in 
vitro dissolution data (50-52).  
It is well known that the bioperformance of certain drug formulations may be 
affected by concomitant administration of food. The assessment of such interactions by 




different carbamazepine formulations i.e., IR suspension, IR tablets, ER tablets and ER 
capsules revealed that the effect of food on drug absorption is formulation-specific (53). 
The PBPK approach was also utilized in the study of Jereb et al. (54) to assess the effect 
of food on the bioequivalence between two formulations containing different drug forms 
(amorphous vs. crystalline). The same research group also published a report on the 
general utility of PBPK/PBBM modeling to predict the fed state bioequivalence for 
pharmaceutical products containing different BCS class drugs (55). Additional studies on 
this subject are also available in literature, and some of them are summarized in the report 
of Kesisoglou (56). 
Examples on the use of PBPK/PBBM modeling in the development of 
pharmaceutical formulations for additional dosing routes are more recent and still 
relatively scarce. The oral cavity model was used to predict drug bioavailability and 
highlight the advantages of various intraoral dosage forms, including sublingual tablets 
(16, 22), orally disintegrating films (18, 19), mucoadhesive buccal tablets (20), buccal 
films (21) and electrospun buccal nanofibrous sheets (17). There are also examples on the 
use of pulmonary PBPK models to assess the formulation-dependent performance of 
inhaled drugs (23, 26). A study of Merdy et al. (57) described the use of the ocular model 
to mechanistically explain the interplay between formulation properties (i.e., drug particle 
size and viscosity) and physiological factors on local dexamethasone bioavailability from 
ophthalmic suspensions. In addition, Merdy et al. (58) conducted a study to compare the 
bioperformance of dexamethasone ophthalmic suspensions vs. ophthalmic solutions 
using the OCAT™ model. The TCAT™ model was used to predict drug absorption 
following transdermal administration of vinorelbine hydrogel formulations, indicating the 
potential for transdermal application of this drug as an alternative to intravenous dosing 
in melanoma treatment (59). Another example of using TCAT™ model refers to 
determination of risperidone transdermal dose (applied as eutectic mixtures of the drug 
and the selected fatty acids) which will provide effective drug plasma levels (60). 
Moreover, a recent study of Mahdi et al. (61) illustrates the use of TCAT™ modeling, in 
combination with in vitro experiments, to support the choice of the suitable solvent for 
rifampicin subcutaneous delivery in the treatment of skin tuberculosis. The attempts to 
use MIDD for the development of long-acting injectables have been summarized in the 
report of Sharan et al. (62).  
Within this section, we should also note that a number of drug-specific PBPK 
models are publicly available in the Open Systems Pharmacology repository 
(http://www.open-systems-pharmacology.org/), and can be used to aid the design of 
novel formulations.  
Regulatory status 
The pharmaceutical industry may largely benefit from PBPK/PBBM modeling just 
by using this tool for internal decision-making during preformulation and formulation 
studies. But an important step forward is the inclusion of M & S data in regulatory 




modeling, and during the past years they have made a great effort to prepare relevant 
guidances on PBPK modeling. Recently issued guidances on this subject include: 
 
1. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) 
modelling and simulation, issued by EMA in December 2018 (effective from July 
2019) (63) 
2. Physiologically Based Pharmacokinetic Analyses — Format and Content 
Guidance for Industry, issued by FDA in August 2018 (64) 
3. The Use of Physiologically Based Pharmacokinetic Analyses — 
Biopharmaceutics Applications for Oral Drug Product, draft version issued by 
FDA in October 2020 (65) 
 
Although the regulatory authorities support the use of PBPK modeling, the number 
of submissions comprising PBPK generated data is still rather limited. Nevertheless, there 
is a clear trend of increase in such submissions, as illustrated in the published reports. 
E.g., there were 67 PBPK-based submissions to EMA up to the end 2015, and 109 
submissions according to the data from 2016 (66, 67). Somewhat higher scores were 
reported from FDA, with 96 submissions up to mid-June 2014, 254 submissions up to the 
end of 2017, and 107 more submissions in 2018-2019 (68, 69). Most of these submissions 
referred to the use of PBPK modeling to assess drug-drug interactions, but also to predict 
drug absorption and bioavailability in special populations (paediatrics, pregnancy) and 
disease states (e.g., hepatic impairment, renal impairment, GI disorders), to assess 
biopharmaceutical aspects of drug delivery (e.g., effect of polymorphism, food effect), 
understand drug’s pharmacokinetic properties and the role of enzymes and transporters, 
provide dose recommendations, compare the outcomes between different dose strengths 
and formulations etc. 
Future directions 
PBPK/PBBM modeling emerged as a powerful tool for the assessment of 
drugs/formulation biopharmaceutical properties, opening a new area of research in the 
field of pharmaceutics. Research groups within academia, research institutions, 
pharmaceutical industry and regulatory agencies enthusiastically embraced in silico 
methods, and nowadays a number of publications, reports, guidelines and regulatory 
submissions stand as a proof of the value of in silico modeling. Yet, in silico modeling is 
a dynamic and ever-growing methodology, and there is a need for further improvements 
in this approach. 
Due to the lack of data on certain physiological mechanisms, the bioperformance 
of some drugs cannot be accurately predicted. Similar issues have emerged in PBPK 
modeling for special populations (e.g., paediatrics, various disease states), when the lack 
of knowledge on the target population physiology and physiological/pathological 




need novel methods for acquiring relevant data. In recent years, progress has been made 
in the development of in vitro methods to estimate drug clearance, and kinetics of 
enzymes- and transporters-mediated processes. Also, novel methods for the assessment 
of transporter abundance are expected to provide more transporter-related data for the in 
silico modeling of drug disposition (70). Special emphasis has been put in the design of 
biopredictive in vitro methods to assess drug dissolution (71-73), and determination of 
the key GI variables that should be included in biopredictive dissolution testing of oral 
drugs (74, 75). These efforts will determine the future of PBBM modeling, which in turn 
may lead to certain changes in the current regulatory requirements for biowaivers.  
Some of the PBPK models e.g., for additional drug dosing routes (nasal, pulmonary, 
ocular, dermal) are still in the early development phase, and need to be refined. The 
inclusion of new features in these models should increase their prediction power, but in 
order to do so, we need predictive mathematical models to enable the translation of in 
vitro to in vivo data. 
As stated above, regulatory authorities support the use of in silico modeling, and 
they should continue to encourage the adoption of these tools within the pharmaceutical 
industry, and submission of PBPK/PBBM-based reports. Furthermore, a wider 
acceptance of PBPK/PBBM modeling implies the need for interdisciplinary teams with 
specialized knowledge and diverse expertise. Some recent reports indicate that 
physiologically-based modeling of biopharmaceutical drug properties has been adopted 
within undergraduate and postgraduate courses (76, 77), and this trend is expected to 
continue in the future.  
Considering the current trends, PBPK/PBBM modeling may soon become a part of 
the formulation development routine. We may even speculate that current models and 
software packages will transcend into model-based platforms for pharmaceutical 
development, which might initiate a transformational change in drug formulation research 
and development. 
Conclusion 
An evident trend in the increased usage of PBPK/PBBM models within the 
pharmaceutical industry, regulatory agencies and academic/research institutions highlight 
the benefits of M & S tools in different phases of drug discovery and formulation 
development. Numerous examples demonstrate that these tools enable time- and cost-
effective development of pharmaceutical products, and may facilitate regulatory decision 
making. In addition, due to the ability to provide data on virtual case studies and virtual 
population studies, PBPK/PBBM modeling may contribute to the formulation of patient-
tailored medicines. 
Regulatory acceptance of PBPK/PBBM modeling has marked a landmark in the 
application of these tools within pharmaceutical industry, and we should expect an 




Physiologically-based in silico models are still improving, and will likely continue 
to evolve in line with the new knowledge on human physiology and relevant physiological 
mechanisms. The growing complexity of these models implies the need for an 
interdisciplinary approach and continuous education of users to obtain adequate modeling 
skills. However, the fulfillment of these needs may require certain changes in the 
pharmaceutical industry organization structure, and refinement of educational (especially 
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Računarski podržano (in silico) modelovanje se danas koristi u različitim oblastima 
farmaceutskih nauka, sa širokom paletom primene. Kao jedan od in silico alata, fiziološki 
zasnovano farmakokinetičko/biofarmaceutsko modelovanje (PBPK/PBBM) se pokazalo posebno 
korisnim u razvoju farmaceutskih preparata. Strategije zasnovane na PBPK/PBBM modelovanju 
se poslednjih godina sve više razmatraju, što se vidi iz izveštaja farmaceutskih kompanija i 
velikog broja publikovanih istraživačkih i revijalnih radova na ovu temu. Takođe, vodeće 
regulatorne agencije su nedavno izdale vodiče koji se odnose na primenu PBPK modelovanja u 
razvoju farmaceutskih preparata. In silico PBPK modelovanje je primenjivo za različite puteve 
primene leka (peroralni, (intra)oralni, parenteralni, inhalacioni, okularni, dermalni itd), mada se 
najveći broj primera iz literature odnosi na modelovanje bioperformansi peroralno primenjenih 
lekova. Kako bi olakšale primenu PBPK modelovanja, nekoliko kompanija je razvilo 
komercijalno dostupne programske pakete, kao što su GastroPlus™, Simcyp™ PBPK Simulator 
i PK-Sim®. U ovom radu su istaknute različite mogućnosti primene PBPK/PBBM modelovanja, 
uključujući osnovne principe, prednosti i ograničenja. Takođe, prikazani su odgovarajući primeri 
koji opisuju praktičnu primenu modelovanja i simulacija u različitim fazama razvoja leka.  
 
Ključne reči: fiziološki zasnovano farmakokinetičko modelovanje (PBPK),  
   fiziološki zasnovano biofarmaceutsko modelovanje (PBBM),  
   model zasnovan razvoj lekova (MIDD), bioperformanse lekova 
 
